Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3681749 | 0.83 | HTR2C (0.70) | HTR2C | |
| SCHEMBL8317538 | 0.83 | HTR2C (0.70) | HTR2C | |
| SCHEMBL3678498 | 0.80 | HTR2C (0.67) | HTR2C | |
| SCHEMBL6642883 | 0.79 | HTR2C (0.65) | HTR2C | |
| SCHEMBL3680468 | 0.78 | HTR2C (0.63) | HTR2C | |
| Hydrochloric Acid SCHEMBL7594335 | 0.78 | HTR2C (0.63) | HTR2C | |
| SCHEMBL5236782 | 0.77 | HTR2C (0.62) | HTR2C | |
| SCHEMBL4922800 | 0.75 | HTR2C (1.00) | HTR2CMAPT | |
| SCHEMBL613412 | 0.75 | HTR2C (0.60) | HTR2C | |
| SCHEMBL13169909 | 0.75 | HTR2C (0.59) | HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943769-B2 | Fluorinated derivative of quinolin-2(1H)-one, method for preparing the same and use thereof as a synthesis intermediate | SANOFI-AVENTIS (FR) | 2011-05-17 | — | — | US | claimed |
| US-20100094005-A1 | FLUORINATED DERIVATIVE OF QUINOLIN-2(1H)-ONE, METHOD FOR PREPARING THE SAME AND USE THEREOF AS A SYNTHESIS INTERMEDIATE | SANOFI-AVENTIS (FR) | 2010-04-15 | — | — | US | claimed |
| CN-1094490-C | Quinolin-2 (1H) -one derivatives as serotonin antagonists | SANOFI SYNTHELABO (FR) | 2002-11-20 | — | — | CN | claimed |
| EP-0850235-B1 | QUINOLEIN-2(1H)-ONE DERIVATIVES AS SEROTONIN ANTAGONISTS | SANOFI SYNTHELABO (FR) | 1999-12-01 | — | — | EP | claimed |
| US-5958924-A | HYPOTENSIVE AGENTS, CARDIOVASCULAR DISORDERS, ANTIISCHEMIC AGENTS, RESTENOSIS, ANTICOALUGANTS, RESPIRATORY SYSTEM DISORDERS | SYNTHELABO (FR) | 1999-09-28 | — | — | US | claimed |
| EP-0934940-A1 | CYTOKINE PRODUCTION INHIBITORS, TRIAZEPINE COMPOUNDS, AND INTERMEDIATES THEREOF | Japan Tobacco Inc. (JP) | 1999-08-11 | — | — | EP | claimed |
| CN-1202168-A | Quinolein-2(1H)-one derivatives as serotonin antagonists | SYNTHELABO (FR) | 1998-12-16 | — | — | CN | claimed |
| EP-0850235-A1 | QUINOLEIN-2(1H)-ONE DERIVATIVES AS SEROTONIN ANTAGONISTS | SYNTHELABO (FR) | 1998-07-01 | — | — | EP | claimed |
| EP-0792880-A1 | OSTEOPOROSIS REMEDY AND TRIAZEPINE COMPOUND | Japan Tobacco Inc. (JP) | 1997-09-03 | — | — | EP | claimed |
| WO-1997010238-A1 | QUINOLEIN-2(1H)-ONE DERIVATIVES AS SEROTONIN ANTAGONISTS | SYNTHELABO (FR) | 1997-03-20 | — | — | WO | claimed |
| EP-2582705-B1 | ANELLATED PYRIDINE COMPOUNDS AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | HOFFMANN LA ROCHE (CH) | 2014-08-06 | — | — | EP | disclosed |
| US-8586579-B2 | Anellated pyridine compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-11-19 | — | — | US | disclosed |
| EP-1724267-B1 | PYRIMIDINE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2013-11-06 | — | — | EP | disclosed |
| EP-1724267-B1 | PYRIMIDINE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2013-11-06 | — | — | EP | disclosed |
| EP-2582705-A1 | ANELLATED PYRIDINE COMPOUNDS AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-04-24 | — | — | EP | disclosed |
| CN-1202168-A | Quinolein-2(1H)-one derivatives as serotonin antagonists | SYNTHELABO (FR) | 1998-12-16 | — | — | CN | disclosed |
| EP-0850235-A1 | QUINOLEIN-2(1H)-ONE DERIVATIVES AS SEROTONIN ANTAGONISTS | SYNTHELABO (FR) | 1998-07-01 | — | — | EP | disclosed |
| EP-0792880-A1 | OSTEOPOROSIS REMEDY AND TRIAZEPINE COMPOUND | Japan Tobacco Inc. (JP) | 1997-09-03 | — | — | EP | disclosed |
| WO-1997010238-A1 | QUINOLEIN-2(1H)-ONE DERIVATIVES AS SEROTONIN ANTAGONISTS | SYNTHELABO (FR) | 1997-03-20 | — | — | WO | disclosed |
| US-4677104-A | Antipsychotic fused-ring pyridinylpiperazine derivatives | BRISTOL-MYERS COMPANY (US) | 1987-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100094005-A1 | FLUORINATED DERIVATIVE OF QUINOLIN-2(1H)-ONE, METHOD FOR PREPARING THE SAME AND USE THEREOF AS A SYNTHESIS INTERMEDIATE | NQO2, SULT2A1, CYP3A7 | HTR2C 391/4885KDM4E 3635/4885MAPT 3044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.